Stocks · News reference

Canaccord Genuity Initiates Coverage On Apotex Health with Buy Rating, Announces Price Target of C$42

Jul 13, 2026, 6:30 PMBenzinga Newsdesk

Canaccord Genuity analyst Tania Armstrong-Whitworth initiates coverage on Apotex Health (TSX:APTX) with a Buy rating and announces Price Target of C$42.

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TSX:APTX

Source: benzinga
Observed: Jul 13, 2026, 6:30 PM
Checked: Jul 13, 2026, 6:30 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 12, 2026, 10:05 AMBenzinga Newsdesk
Apotex Health Q1 Adj. EPS $0.70 Beats $0.51 Estimate, Sales $848.000M Beat $840.780M Estimate
Apotex Health (TSX:APTX) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.51 by 37.25 percent. This is a 22.22 percent decrease over earnings of $0.90 per share from the
Read original at benzinga
TSX:APTX
BenzingaJul 6, 2026, 11:11 AMBenzinga Newsdesk
Scotiabank Initiates Coverage On Apotex Health with Sector Outperform Rating, Announces Price Target of C$40
Read original at benzinga
TSX:APTX

Canaccord Genuity Initiates Coverage On Apotex Health with Buy Rating, Announces Price Target of C$42

Connected markets

Related headlines

Apotex Health Q1 Adj. EPS $0.70 Beats $0.51 Estimate, Sales $848.000M Beat $840.780M Estimate

Scotiabank Initiates Coverage On Apotex Health with Sector Outperform Rating, Announces Price Target of C$40